---
layout: post
title: "中国药企入围MPP默沙东口服新冠药仿制协议名单，香港医药ETF开盘上涨1%"
date: 2022-01-21 09:36:23 +0800
categories: emnews
tags: 东财滚动新闻
---
> 中国药企入围了协议名单，复星医药、博瑞医药、石家庄龙泽制药与上海迪赛诺获许可同时生产Molnupiravir的原料药和成品药，维亚生物旗下朗华制药则获许生产Molnupiravir的原料药。香港医药ETF（513700）开盘上涨1%。（天天基金网）

<!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/1.513700" data-code="513700|1|1" data-code2="513700|1|9|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=1.513700&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 513700_0" data-code="K 513700|1|1" data-code2="K 513700|1|9|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>中国药企入围了协议名单，<span id="stock_1.600196"><a href="http://quote.eastmoney.com/unify/r/1.600196" class="keytip" data-code="1,600196">复星医药</a></span><span id="quote_1.600196"></span>、<span id="stock_1.688166"><a href="http://quote.eastmoney.com/unify/r/1.688166" class="keytip" data-code="1,688166">博瑞医药</a></span><span id="quote_1.688166"></span>、石家庄龙泽制药与上海迪赛诺获许可同时生产Molnupiravir的原料药和成品药，<span id="Info.116.01873"><a href="http://quote.eastmoney.com/unify/r/116.01873" class="keytip" data-code="116,01873">维亚生物</a></span>旗下朗华制药则获许生产Molnupiravir的原料药。香港医药<span id="Info.3139"><a href="http://fund.eastmoney.com/ETFN_jzzzl.html" class="infokey">ETF</a></span>(513700)开盘上涨1%。</p>

<http://finance.eastmoney.com/news/1353,202201212256104496.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)